ArticleJournal of molecular histology2025
Robinin decreases myocardial ischemia/reperfusion injury via Nrf2 anti-oxidative effects mediated by Akt/GSK3β/Fyn in hypercholesterolemic rats.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network Pharmacology and Untargeted Metabolomics Analysis of the Protective Mechanisms of Total Flavonoids from Chuju in Myocardial Ischemia-Reperfusion Injury.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robinin (RB) is an accepted antioxidant herbal product with known cardio-protective activity. To explore the anti-oxidative potential of RB in treating myocardial ischemia or reperfusion (MI/RI) damage in rats after inducing hypercholesterolemia (HC). HC was induced by administering cholesterol (2%) to rats for eight weeks. The rats were given RB (50 mg/kg bw) for the last two weeks. The rats were arbitrarily divided into four groups: (Group I) normal control, (Group II) hypercholesterolemic (HC) alone, (Group III) HC + RB (50 mg/kg body weight), and (Group IV) RB alone (50 mg/kg body weight). LV-developed pressure (LVDP), and left ventricular end-diastolic pressure (LVEDP) were recorded during the perfusion process. Histopathology staining was used to analyze liver and kidney damage in heart tissue (H&E, MT, and PAS stains), and in silico techniques, such as molecular docking and MD simulation, were employed. Results revealed that RB administration reduced MI/RI in HC rats due to Akt/GSK3β/Fyn-as facilitated Nrf2 anti-oxidative function. Administering RB to HC rats resulted in increased expression of Akt, whereas it reduced the Fyn and GSK3β levels, which activated Nrf2 activity. When RB is administered to HC rats. Glide (a Schrodinger module) was used to dock RB with NQO1, Nrf-2, HO-1, GSK-3β, and Akt to select the best interacting drug action on inflammatory markers for the therapeutic action of RB and followed OH-1 and Nrf2 MD simulation study were carried out. These results highlight how Nrf2 antioxidative effects are mediated by Akt/GSK3β/Fyn are enhanced by RB, protecting the HC heart from MI/RI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.